CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension

Perivascular infiltrates composed of macrophages and lymphocytes have been described in lung biopsies of patients displaying pulmonary arterial hypertension (PAH), suggesting that circulating inflammatory cells can be recruited in affected vessels. CX3C chemokine fractalkine is produced by endothelial cells and promotes leukocyte recruitment, but unlike other chemokines, it can capture leukocytes rapidly and firmly in an integrin-independent manner under high blood flow. We therefore hypothesized that fractalkine may contribute to pulmonary inflammatory cell recruitment in PAH. Expression and function of the fractalkine receptor (CX3CR1) were studied by use of triple-color flow cytometry on circulating T-lymphocyte subpopulations in freshly isolated peripheral blood mononuclear cells from control subjects and patients with PAH. Plasma-soluble fractalkine concentrations were measured by enzyme-linked immunosorbent assay. Finally, fractalkine mRNA and protein expression were analyzed in lung samples by reve...

[1]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[2]  C. Blobel,et al.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.

[3]  A. Foussat,et al.  Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. , 2001, Blood.

[4]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[5]  A. Quyyumi,et al.  Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.

[6]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[7]  L. Anderson,et al.  CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein , 2001, Nature Immunology.

[8]  D. C. Woodruff,et al.  Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. , 2001, Arthritis and rheumatism.

[9]  E. Farber,et al.  Cellular localization of fractalkine at sites of inflammation: antigen‐presenting cells in psoriasis express high levels of fractalkine , 2001, The British journal of dermatology.

[10]  S. Gordon,et al.  Linked Chromosome 16q13 Chemokines, Macrophage-Derived Chemokine, Fractalkine, and Thymus- and Activation-Regulated Chemokine, Are Expressed in Human Atherosclerotic Lesions , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[11]  P. Allavena,et al.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. , 2001, The Journal of clinical investigation.

[12]  S. Lira,et al.  Generation and Analysis of Mice Lacking the Chemokine Fractalkine , 2001, Molecular and Cellular Biology.

[13]  D. Soler,et al.  Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.

[14]  P. Murphy,et al.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.

[15]  K. Matsushima,et al.  Upregulation of Fractalkine in Human Crescentic Glomerulonephritis , 2001, Nephron.

[16]  S. Gordon,et al.  The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. , 2001, The American journal of pathology.

[17]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[18]  D. Patel,et al.  A Role for Fractalkine and Its Receptor (CX3CR1) in Cardiac Allograft Rejection1 , 2000, The Journal of Immunology.

[19]  S. Rich,et al.  Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". , 2000, Circulation.

[20]  M. Humbert,et al.  Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension , 2000, Circulation.

[21]  I. Charo,et al.  Unique Role of the Chemokine Domain of Fractalkine in Cell Capture , 2000, The Journal of Biological Chemistry.

[22]  C. Sassetti,et al.  Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane‐bound chemokine expressed constitutively in diverse cells of the skin , 2000 .

[23]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[24]  S. Goda,et al.  CX3C-Chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells Through Integrin-Dependent and -Independent Mechanisms1 , 2000, The Journal of Immunology.

[25]  H. Erickson,et al.  Ultrastructure and Function of the Fractalkine Mucin Domain in CX3C Chemokine Domain Presentation* , 2000, The Journal of Biological Chemistry.

[26]  Sandra A. Kinnear,et al.  Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System1 , 2000, The Journal of Immunology.

[27]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[28]  A. Foussat,et al.  Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human , 2000, European journal of immunology.

[29]  L. Feng,et al.  Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart , 1999, Journal of leukocyte biology.

[30]  T. Schall,et al.  Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up‐regulated upon dendritic cell maturation , 1999, European journal of immunology.

[31]  Y. Xia,et al.  Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. , 1999, Kidney international.

[32]  I. Charo,et al.  Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction , 1999, The Journal of Biological Chemistry.

[33]  G. Thiene,et al.  Effective immunosuppressive therapy in a patient with primary pulmonary hypertension , 1999, Thorax.

[34]  A. Foussat,et al.  Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. , 1999, AIDS.

[35]  M. Humbert,et al.  Treatment of pulmonary hypertension secondary to connective tissue diseases , 1999, Thorax.

[36]  D. Patel,et al.  Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow , 1998, The Journal of experimental medicine.

[37]  C. Combadière,et al.  Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. , 1998, The Journal of biological chemistry.

[38]  W. Streit,et al.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Humbert,et al.  Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. , 1998, Chest.

[40]  K. Matsushima,et al.  Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[41]  M. Humbert,et al.  Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.

[42]  F. Authier,et al.  Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. , 1998, American journal of respiratory and critical care medicine.

[43]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[44]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[45]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[46]  P. Galanaud,et al.  Quantification of cytokine gene expression by competitive PCR using a colorimetric assay. , 1995, European cytokine network.

[47]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[48]  N. Voelkel,et al.  Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. , 1994, American journal of respiratory cell and molecular biology.

[49]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[50]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[51]  F. Arnett,et al.  Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. , 1992, The American journal of medicine.

[52]  J. Loscalzo.  Endothelial dysfunction in pulmonary hypertension. , 1992, The New England journal of medicine.

[53]  D. Goeddel,et al.  Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES , 1990, Nature.